BioSpace News Archive

Deep Lens announced that Kamala Maddali, DVM, PhD, has been appointed to the Society for Clinical Research Sites Oncology Program Board.

RUC-4 is the first and only GPIIb/IIIa inhibitor that is in clinical development as a simple, single subcutaneous injection treatment to potently and rapidly block all platelet aggregation pathways to improve outcomes for heart attack patients SAN DIEGO--( BUSINESS WIRE )-- CeleCor Therapeutics, Inc. announced positive data from the company’s completed phase 1 clinical study of RUC-4 which was published in the Journal of the American Heart Associa

Industry-Leading Patient Support and Access Company Advances Mission to Simplify the Specialty Patient Journey with Strategic Investment in HelpAround

The American Diabetes Association (ADA) announced that it has invested $1 million to fund 10 research projects investigating the link between COVID-19 and diabetes. The awarded funds will support basic, transl

Analysis of 18 million de-identified lab tests also reveals shift in positivity rate toward older women, with more females “aging out” of annual screening guidelines that end at age 25

Huami Corp. (NYSE: HMI) today announced that it will be participating in the Wells Fargo Securities 3 rd Annual Virtual Consumer Conference. COO Mike Yeung and IRO Brad Samson will be conducting one-on-one meetings on September 16 and 17. Interested investors can contact their Wells Fargo salesperson for availability. Huami’s miss

Creates patient access to first-of-its-kind, personalized ctDNA test to inform adjuvant treatment decisions and detect recurrence earlier than standard diagnostic tools

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that the US Court of Appeals for the Federal Circuit today upheld a ruling by the US District Court for the District of Nevada finding that Hikma’s generic version of Vascepa ®1 (icosapent ethyl) 1gm does not infringe any valid claim of six key Amar

Today, Surface Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapeutics in eye care, announced that Perry Sternberg will be joining the Board of Directors. Sternberg o

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Camille L. Bedrosian, M.D. as an independent member of its board of directors. Dr. Bedrosian brings over 25 years of experience leading drug development efforts for rare disease products an